Summary
In a single-dose crossover study Captopril (SQ 14225), 1 mg/kg body weight, and Nifedipine (Bay a 1040) 20 mg were administered orally to 12 hospitalized patients with essential hypertension (Stage 1 or 2, W. H. O.). Both drugs significantly reduced blood pressure, but each dose acted differently: the mean maximum arterial pressure reduction was faster and greater with Nifedipine than with Captopril: −23±2% at 37±15 min and −17±1% at 86±25 min, respectively. Captopril inhibited angiotensin II and aldosterone production, but did not accelerate heart rate or stimulate vasopressin release. Nifedipine stimulated vasopressin release and increased heart rate, but the renin angiotensin aldosterone system was not significantly affected. The blood pressure reduction was related to the initial level of activation of the renin angiotensin system only for Captopril. The blood pressure reduction induced by one drug was not related to that produced by the other in the same patient.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rubin B, Antonaccio MJ (1980) Captopril. In: Scriabine A (ed) Pharmacology of antihypertensive drugs. Raven Press, New York, pp 21–42
Guazzi M, Fiorentini C, Olivari M, Bartorelli A, Necchi G, Polese A (1980) Short and long term efficacy of a calcium antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension. Circulation 61: 913–919
Thibonnier M, Bonnet F, Corvol P (1980) Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertension. Eur J Clin Pharmacol 17: 161–164
Aoki K, Kondo G, Mochizuki A, Yoshida T, Kato S, Kato K, Takikawa K (1978) Antihypertensive effect of cardiovascular Ca++ antagonist in hypertensive patients in the absence and presence of beta adrenergic blockade. Am Heart J 96: 218–226
Aoki I, Yoshida T, Kato S, Tazumi K, Sato I, Takikawa K, Hotta K (1976) Hypotensive action and increased plasma renin activity by Ca++ antagonist (nifedipine) in hypertensive patients. Jpn Heart J 17: 479–484
Lederballe-Pedersen O, Mikkelsen E, Christensen NJ, Kornerup HJ, Pedersen EB (1979) Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension. Eur J Clin Pharmacol 15: 235–240
Corvol P, Menard J, Bertagna X (1973) Dosages radioimmunologiques de l'aldostérone et de l'activité rénine plasmatique. Ann Endocrinol 34: 57–65
Thibonnier M, Soto ME, Marchetti J, Corvol P, Menard J, Milliez P (1980) Advantages and Drawbacks of AVP radioimmunoassay in plasma and urine of normal subjects. Horm Metab Res (in press)
Fressinaud P, Corvol P, Menard J (1974) Radioimmunoassay of urinary antidiuretic hormone in man: stimulation — suppression tests. Kidney Int 6: 184–190
Corvol P, Oblin ME, Degoulet P, Fressinaud P, Menard J (1977) Effect of acute potassium loading on plasma renin and on urinary aldosterone in rats. Endocrinology 100: 1008–1013
Brunner HR, Gavras H, Waeber B, Kershaw R, Turini GA, Vukovick RA, McKinstry D, Gavras I (1979) Oral angiotension-converting enzyme inhibition in long-term treatment of hypertensive patients. Ann Intern Med 90: 19–23
Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S, Gavras I, Vukovich RA, McKinstry D (1978) Antihypertensive effect of the oral angiotensin-converting enzyme inhibitor SQ 14225, in man. N Engl J Med 298: 991–998
Morganti A, Pickering T, Lopez Ovejero J, Laragh J (1980) Endocrine and cardiovascular influences of converting enzyme inhibition with SQ 14225 in hypertensive patients in the supine position and during head-up tilt before and after sodium depletion. J Clin Endocrinol Metab 50: 748–754
Olivari MT, Bartorelli C, Polese A, Fiorentini C, Moruzzi P, Guazzi M (1979) Treatment of hypertension with Nifedipine, a calcium antagonist agent. Circulation 59: 1056–1062
Ellrodt G, Christopher Y, Chew C, Singh BN (1980) Therapeutic implications of slow-channel blockade in cardiocirculatory disorders. Circulation 62: 669–679
Fray JCS (1980) Stimulus secretion coupling of renin. Circ Res 47: 485–492
Hashimoto K, Ono H, O'Hara N (1978) Blockade of renal autoregulatory vasoconstriction by calcium antagonists. Springer, Berlin Heidelberg New York, pp 221–229
Thibonnier M, Soto ME, Menard J, Corvol P, Milliez P (1980) Inhibition de l'aldosterone et de la vasopressine dans l'hypertension artérielle traitée par Captopril. Ann Endocrinol 41: 89c
Davies R, Forsling ML, Slater JDH (1977) The interrelationship between the release of renin and vasopressin as defined by orthostasis and propranolol. J Clin Invest 60: 1438–1441
Atkinson AB, Brown JJ, Davies DL (1979) Hyponatraemic hypertensive syndrome with renal artery occlusion corrected by Captopril. Lancet 2: 606–609
Crofton JT, Share L, Horovitz Z (1979) The effect of SQ 14225 on systolic blood pressure and urinary excretion of vasopressin in the developing spontaneously hypertensive rat. Hypertension 1: 462–467
Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore JJ (1980) Captopril-induced changes in prostaglandin production. J Clin Invest 65: 1257–1264
Klutsch K, Schmidt P, Grosswendt J (1972) Der Einfluß von Bayer a 1040 auf die Nierenfunktion des Hypertonikers. Arzneim-Forsch 22: 377–380
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Soto, M.E., Thibonnier, M., Sire, O. et al. Antihypertensive and hormonal effects of single oral doses of Captopril and Nifedipine in essential hypertension. Eur J Clin Pharmacol 20, 157–161 (1981). https://doi.org/10.1007/BF00544592
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544592